CASI Intrinsic Valuation and Fundamental Analysis - CASI Pharmaceuticals Inc - Alpha Spread
C

CASI Pharmaceuticals Inc
NASDAQ:CASI

Watchlist Manager
CASI Pharmaceuticals Inc
NASDAQ:CASI
Watchlist
Price: 6.54 USD -3.25% Market Closed
Market Cap: 87.6m USD
Have any thoughts about
CASI Pharmaceuticals Inc?
Write Note

Intrinsic Value

The intrinsic value of one CASI stock under the Base Case scenario is 9.27 USD. Compared to the current market price of 6.54 USD, CASI Pharmaceuticals Inc is Undervalued by 29%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CASI Intrinsic Value
9.27 USD
Undervaluation 29%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation Backtest
CASI Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CASI based on its intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?
How do you feel about CASI?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about CASI Pharmaceuticals Inc

Provide an overview of the primary business activities
of CASI Pharmaceuticals Inc.

What unique competitive advantages
does CASI Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does CASI Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in CASI Pharmaceuticals Inc recently?

Summarize the latest earnings call
of CASI Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for CASI Pharmaceuticals Inc.

Provide P/S
for CASI Pharmaceuticals Inc.

Provide P/E
for CASI Pharmaceuticals Inc.

Provide P/OCF
for CASI Pharmaceuticals Inc.

Provide P/FCFE
for CASI Pharmaceuticals Inc.

Provide P/B
for CASI Pharmaceuticals Inc.

Provide EV/S
for CASI Pharmaceuticals Inc.

Provide EV/GP
for CASI Pharmaceuticals Inc.

Provide EV/EBITDA
for CASI Pharmaceuticals Inc.

Provide EV/EBIT
for CASI Pharmaceuticals Inc.

Provide EV/OCF
for CASI Pharmaceuticals Inc.

Provide EV/FCFF
for CASI Pharmaceuticals Inc.

Provide EV/IC
for CASI Pharmaceuticals Inc.

Show me price targets
for CASI Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for CASI Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for CASI Pharmaceuticals Inc?

What are the Net Income projections
for CASI Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for CASI Pharmaceuticals Inc?

What are the EPS projections
for CASI Pharmaceuticals Inc?

How accurate were the past EPS estimates
for CASI Pharmaceuticals Inc?

What are the EBIT projections
for CASI Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for CASI Pharmaceuticals Inc?

Compare the revenue forecasts
for CASI Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of CASI Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of CASI Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of CASI Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of CASI Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing CASI Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of CASI Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for CASI Pharmaceuticals Inc.

Provide ROE
for CASI Pharmaceuticals Inc.

Provide ROA
for CASI Pharmaceuticals Inc.

Provide ROIC
for CASI Pharmaceuticals Inc.

Provide ROCE
for CASI Pharmaceuticals Inc.

Provide Gross Margin
for CASI Pharmaceuticals Inc.

Provide Operating Margin
for CASI Pharmaceuticals Inc.

Provide Net Margin
for CASI Pharmaceuticals Inc.

Provide FCF Margin
for CASI Pharmaceuticals Inc.

Show all solvency ratios
for CASI Pharmaceuticals Inc.

Provide D/E Ratio
for CASI Pharmaceuticals Inc.

Provide D/A Ratio
for CASI Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for CASI Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for CASI Pharmaceuticals Inc.

Provide Quick Ratio
for CASI Pharmaceuticals Inc.

Provide Current Ratio
for CASI Pharmaceuticals Inc.

Provide Cash Ratio
for CASI Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for CASI Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for CASI Pharmaceuticals Inc?

What is the current Free Cash Flow
of CASI Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for CASI Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
CASI Pharmaceuticals Inc

Current Assets 59.3m
Cash & Short-Term Investments 18.8m
Receivables 10.1m
Other Current Assets 30.4m
Non-Current Assets 15.9m
Long-Term Investments 1.7m
PP&E 11.6m
Intangibles 1.8m
Other Non-Current Assets 766k
Current Liabilities 16.7m
Accounts Payable 4.4m
Accrued Liabilities 12.3m
Non-Current Liabilities 34.4m
Long-Term Debt 18.9m
Other Non-Current Liabilities 15.5m
Efficiency

Earnings Waterfall
CASI Pharmaceuticals Inc

Revenue
33.9m USD
Cost of Revenue
-13.8m USD
Gross Profit
20.1m USD
Operating Expenses
-45.3m USD
Operating Income
-25.3m USD
Other Expenses
-1.7m USD
Net Income
-27m USD

Free Cash Flow Analysis
CASI Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CASI Profitability Score
Profitability Due Diligence

CASI Pharmaceuticals Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
ROIC is Increasing
26/100
Profitability
Score

CASI Pharmaceuticals Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

CASI Solvency Score
Solvency Due Diligence

CASI Pharmaceuticals Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Positive Net Debt
38/100
Solvency
Score

CASI Pharmaceuticals Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CASI Price Targets Summary
CASI Pharmaceuticals Inc

Wall Street analysts forecast CASI stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CASI is 6.12 USD with a low forecast of 6.06 USD and a high forecast of 6.3 USD.

Lowest
Price Target
6.06 USD
7% Downside
Average
Price Target
6.12 USD
6% Downside
Highest
Price Target
6.3 USD
4% Downside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CASI?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for CASI is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about CASI dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

CASI Price
CASI Pharmaceuticals Inc

1M 1M
+3%
6M 6M
+110%
1Y 1Y
+221%
3Y 3Y
-52%
5Y 5Y
-80%
10Y 10Y
-64%
Annual Price Range
6.54
52w Low
2
52w High
7.85
Price Metrics
Average Annual Return -41.02%
Standard Deviation of Annual Returns 38.56%
Max Drawdown -96%
Shares Statistics
Market Capitalization 87.5m USD
Shares Outstanding 13 401 400
Percentage of Shares Shorted 2.46%

Competitive Landscape

Ownership

CASI Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

CASI Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

87.5m USD

Dividend Yield

0%

Description

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company is headquartered in Rockville, Maryland and currently employs 168 full-time employees. The firm is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States and throughout the world. The company is also focused on acquiring, developing, and commercializing products that augment its hematology-oncology therapeutic focus as well as other areas of unmet medical need. The Company’s operations in China are conducted primarily through its subsidiaries, which include CASI Pharmaceuticals (China) Co., Ltd. (CASI China), which is wholly owned and is located in Beijing, China, and CASI Pharmaceuticals (Wuxi) Co., Ltd. (CASI Wuxi), which is located in Wuxi, China. Its commercial product, EVOMELA, is developed for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The Company’s other core hematology/oncology assets in its pipeline include CNCT19, BI-1206, CB-5339 and CID-103.

Contact

MARYLAND
Rockville
9620 Medical Center Dr Ste 300
+12408642600.0
www.casipharmaceuticals.com

IPO

1996-06-12

Employees

168

Officers

See Also

Discover More
What is the Intrinsic Value of one CASI stock?

The intrinsic value of one CASI stock under the Base Case scenario is 9.27 USD.

Is CASI stock undervalued or overvalued?

Compared to the current market price of 6.54 USD, CASI Pharmaceuticals Inc is Undervalued by 29%.

Back to Top